EVRA 200 MCG / 24 HOUR
NORELGESTROMIN : 200 MCG / 24 HOUR ETHINYL ESTRADIOL : 35 MCG / 24 HOUR · DIN 02248297 · SEARCHLIGHT PHARMA INC
Health Canada status: MARKETED
What is EVRA?
EVRA 200 MCG / 24 HOUR contains NORELGESTROMIN : 200 MCG / 24 HOUR ETHINYL ESTRADIOL : 35 MCG / 24 HOUR. It is listed in the Health Canada Drug Product Database under DIN 02248297, held by SEARCHLIGHT PHARMA INC, supplied as PATCH (EXTENDED RELEASE) for TRANSDERMAL administration. Health Canada currently lists it as marketed, status dated 25-Oct-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EVRA used for?
Prevention of pregnancy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02248297 |
|---|---|
| Brand name | EVRA |
| Generic / active ingredient | NORELGESTROMIN : 200 MCG / 24 HOUR ETHINYL ESTRADIOL : 35 MCG / 24 HOUR |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 200 MCG / 24 HOUR |
| Dosage form | PATCH (EXTENDED RELEASE) |
| Route of administration | TRANSDERMAL |
| Schedule | Prescription |
| ATC code | G03AA13 NORELGESTROMIN AND ESTROGEN |
| AHFS class | 68:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Oct-2022 |
| Original market date | 2003-12-24 00:00:00 |
How is it administered?
Apply one patch weekly for 3 weeks, followed by a 7-day patch-free interval. Apply to buttock, abdomen, upper outer arm, or upper torso. Do not exceed 7-day patch-free interval.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C (implied by standard Canadian monograph sections, though specific text was truncated, the header for section 11 is present).
How is it supplied?
Cartons containing 3 systems each. Each system is sealed within a protective pouch.
Contraindications
Hypersensitivity; history of VTE, thrombophlebitis, or thromboembolic disorders; cardiovascular disease; liver disease/tumours; breast or estrogen-dependent cancer; undiagnosed vaginal bleeding; pregnancy.
Warnings and precautions
Increased risk of venous thromboembolism (VTE). Risk increases with obesity (BMI ≥ 30 kg/m2). Smoking increases cardiovascular risk, especially in women over 35. Does not protect against STIs.
What can be used instead?
Other Canadian products sharing ATC code G03AA13 NORELGESTROMIN AND ESTROGEN. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| EVRA -(6/0.75) | 0.75 MG | PATCH (EXTENDED RELEASE) | JANSSEN INC | CANCELLED POST MARKET | DIN 02246340 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.